17. Neuromuscular Blockade in ARDS (ACURASYS vs. ROSE)

Quick Recap

Cross-cutting protocol — companion to the ARDS protocol (Respiratory System), Pain Assessment & Sedation Strategy, and Early Mobilization & Rehabilitation protocols. Addresses a genuinely instructive discordance between two well-conducted trials separated by roughly a decade, where the explanation lies substantially in how the surrounding standard of care itself evolved between the two trials — a distinct pattern from purely conflicting evidence, worth understanding in its own right.

1. Definition

Early neuromuscular blockade in ARDS: continuous infusion of a neuromuscular blocking agent (specifically cisatracurium in both major trials) for a defined early period (48 hours) in patients with moderate-to-severe ARDS, historically proposed to improve ventilator synchrony, reduce work of breathing, reduce alveolar fluid accumulation, and potentially reduce ventilator-induced lung injury — at the cost of requiring concomitant deep sedation and carrying a theoretical risk of ICU-acquired weakness.

The specific, unusual value of this evidence pair: ACURASYS (2010) and ROSE (2019) used the same agent, same dose, same duration — a genuinely rare degree of methodological alignment between two large trials testing the same intervention roughly a decade apart — yet reached different conclusions. This makes the context surrounding the intervention (sedation depth, proning rates, PEEP strategy) the leading candidate explanation for the discordance, rather than the intervention itself being ambiguous or the trials being poorly comparable in their core design.

2. Pathophysiology

The proposed mechanistic benefits of neuromuscular blockade in ARDS include: elimination of patient-ventilator dyssynchrony (which can itself worsen lung injury via breath-stacking and excessive transpulmonary pressure swings), reduced work of breathing and associated oxygen consumption, and reduced spontaneous respiratory effort-driven lung stress in already-injured lung tissue (a mechanism related to, but distinct from, the ventilator-induced lung injury concept addressed in the ARDS protocol's lung-protective ventilation strategy).

The cost side of the mechanistic ledger: achieving neuromuscular blockade requires concomitant deep sedation (a paralyzed, awake patient is both inhumane and clinically dangerous), which directly conflicts with the light-sedation, delirium-minimizing principles established in the Pain Assessment & Sedation Strategy and Delirium Screening & Management protocols elsewhere in this library. Additionally, prolonged immobility from combined paralysis and deep sedation is mechanistically linked to ICU-acquired weakness (cross-reference Early Mobilization & Rehabilitation and Post-Intensive Care Syndrome protocols). This tension — between a plausible lung-protective benefit and a plausible sedation/immobility-related cost — is the central mechanistic reason the intervention's net benefit is sensitive to the surrounding standard of care, which is precisely what changed between ACURASYS and ROSE (Section 11).

3. Immediate Stabilization (ABCDE) — Not Applicable in the Traditional Sense

This protocol addresses a specific adjunctive therapy decision within ARDS management rather than an acute stabilization scenario; cross-reference the ARDS protocol (Respiratory System) for the full lung-protective ventilation and overall stabilization framework this decision sits within.

Checklist — if neuromuscular blockade is being considered:

4. Focused History

• ARDS severity and PaO2/FiO2 ratio trajectory
• Current ventilator synchrony and sedation depth/requirement
• Hemodynamic stability (relevant given the cardiovascular adverse event signal in ROSE — Section 11)
• Concurrent or planned proning status

5. Comprehensive System-wise Examination

• Respiratory: ventilator synchrony, work of breathing, PaO2/FiO2 trend
• Cardiovascular: hemodynamic stability and rhythm, given the specific cardiovascular adverse event signal identified in ROSE
• Neuromuscular: baseline strength assessment where feasible, relevant to subsequent ICU-acquired weakness risk assessment (cross-reference Early Mobilization & Rehabilitation protocol)

POCUS integration: not a primary component of this specific decision; cardiac/lung ultrasound remain relevant to the broader ARDS assessment per that protocol.

6. Syndrome Identification — Reframed as Decision Classification

• Moderate-to-severe ARDS, genuine ventilator dyssynchrony not resolved by sedation/ventilator adjustment, contemporary light-sedation/proning-forward practice environment: current evidence (ROSE) does not support routine early neuromuscular blockade as beneficial in this context — optimize sedation, ventilator settings, and proning first
• Severe hypoxemia with dyssynchrony where proning and optimized ventilation are not yet fully implemented: a more nuanced, individualized consideration given the ACURASYS-vs-ROSE discordance (Section 11) — not a clear indication, but also not definitively excluded
• Refractory dyssynchrony/hypoxemia despite optimized sedation, ventilation, and proning: neuromuscular blockade may reasonably be considered as a rescue measure in this narrower, more refractory population, though this specific scenario has not been separately, rigorously tested

7. Differential Diagnosis — Not a Traditional Differential

Cross-reference the ARDS protocol (Respiratory System) for the underlying diagnostic and severity framework; this protocol's relevant consideration is whether persistent dyssynchrony/hypoxemia reflects a genuine indication for neuromuscular blockade specifically, versus inadequately optimized sedation, ventilator settings, or proning that should be addressed first.

8. Severity/Risk Assessment

PaO2/FiO2 ratio: both major trials enrolled moderate-to-severe ARDS by this standard metric; a post-hoc ACURASYS subgroup analysis specifically found the mortality benefit signal concentrated in patients with PaO2/FiO2 <120 mmHg, suggesting the most severely hypoxemic patients may be where any residual benefit signal is most plausible, though this was not the trial's primary, pre-specified analysis.

Ventilatory ratio (VR): a post-hoc ROSE trial analysis specifically examined whether neuromuscular blockade modified the relationship between ventilatory ratio and mortality — an emerging area of investigation into whether specific physiological subphenotypes might respond differently to neuromuscular blockade, not yet translated into a validated clinical selection tool.

9. Investigations

Not primarily a diagnostic workup; the relevant "investigation" is ongoing ventilator synchrony and hemodynamic monitoring during any neuromuscular blockade infusion, given the specific cardiovascular adverse event signal identified in ROSE.

10. Point-of-Care Ultrasound — Not a Primary Component

11. Evidence-Based Management — The ACURASYS-to-ROSE Evidence Arc, Explained

ACURASYS (2010) — The Original, Practice-Establishing Trial

• ACURASYS trial (multicenter, 20 ICUs in France, n=340, moderate-to-severe ARDS): early 48-hour cisatracurium infusion with deep sedation vs. usual care with deep sedation (both arms deeply sedated — a critical, era-specific design feature) — 28-day mortality 23.7% (cisatracurium) vs. 33.3% (placebo), p=0.05 — a substantial, statistically significant absolute mortality reduction of roughly 9–10 percentage points
• This result, though achieved via an adjusted analysis of the primary endpoint (a detail worth noting for interpretive precision), was influential enough to establish early neuromuscular blockade as a weakly recommended ARDS therapy, despite uptake remaining variable across institutions given ongoing concerns about ICU-acquired weakness
• Notably, in ACURASYS, 50% of patients were proned

The ICU Practice Landscape Changed Substantially in the Intervening Decade

• Between ACURASYS (2010) and ROSE (2019), ICU sedation practice shifted decisively toward light sedation as the default standard (cross-reference Pain Assessment & Sedation Strategy protocol's discussion of the broader evidence base driving this shift), a genuinely different practice environment than the deep-sedation-as-usual-care context in which ACURASYS was conducted
• Proning's own mortality benefit (PROSEVA trial, cross-reference ARDS protocol) became more firmly established and widely adopted during this same period

ROSE (2019) — The Contemporary Re-Evaluation

• ROSE trial (PETAL Network/NHLBI, multicenter, n=1,066, moderate-to-severe ARDS): early 48-hour cisatracurium with concomitant deep sedation (intervention group) vs. usual care with light sedation targets (control group; notably, 17% of control-arm patients still received as-needed cisatracurium) — designed specifically to be consistent with ACURASYS's agent, dose, and duration, while reflecting contemporary light-sedation-as-comparator practice
• Primary outcome (90-day mortality): 42.5% (neuromuscular blockade) vs. 42.8% (control), p=0.93 — no significant difference; the trial was stopped early for futility
• No benefit on secondary outcomes: 28-day mortality, ventilator-free days, ICU-free days, and out-of-hospital days were all similar between groups
• Signal of harm: an excess of 10 cardiovascular events in the neuromuscular blockade group, largely conduction system abnormalities (bradycardia, atrial fibrillation, heart block), including an excess of 4 cardiac arrests
• Only 16% of ROSE patients were proned, compared to 50% in ACURASYS — a substantial difference in a co-intervention with its own independently established mortality benefit

Why the Discordance — Leading Explanations

• Design difference in the control/comparator arm is the most consistently cited explanation: ACURASYS compared cisatracurium-plus-deep-sedation against deep-sedation-alone (both arms deeply sedated); ROSE compared cisatracurium-plus-deep-sedation against light-sedation usual care — meaning ROSE's control arm itself likely captured much of the ventilator-synchrony and comfort benefit that neuromuscular blockade was originally theorized to provide, via a fundamentally different (and, per the broader sedation literature, independently beneficial) mechanism
• Differential proning rates (50% in ACURASYS vs. 16% in ROSE) represent a second major confound — if proning itself provides much of the physiological benefit neuromuscular blockade was theorized to add, a trial with substantially higher proning rates in both arms (as in ACURASYS) may show a different neuromuscular-blockade-specific effect than one where proning was used far less (as in ROSE)
• The 90-day mortality rate was similar between the two trials' control groups, which somewhat argues against simply attributing the discordance to a sicker or fundamentally different patient population between the trials — reinforcing that the co-interventions and comparator design differences are the more compelling explanation than a change in the underlying patient population's baseline severity
• A subsequent meta-analysis found that when the trial using a high-PEEP-and-light-sedation strategy (i.e., ROSE) was excluded, remaining pooled data showed improvement across mortality outcomes — a finding that itself illustrates how sensitive the pooled evidence is to exactly this comparator-design question, rather than resolving it independently

Practical Synthesis

Current evidence, reflecting contemporary practice standards (light sedation as default, proning used more consistently), does not support routine early neuromuscular blockade for moderate-to-severe ARDS. The ACURASYS finding should not be dismissed as simply wrong — it was a well-conducted trial that accurately reflected the standard of care and outcomes achievable in its era — but its result does not straightforwardly translate into current practice, where the comparator (light sedation, more consistent proning) has itself changed in ways that plausibly capture much of neuromuscular blockade's originally proposed benefit through different, arguably more favorable mechanisms (avoiding the deep-sedation and immobility costs entirely). Optimizing sedation, ventilator settings, and proning first, per current standard ARDS management (cross-reference ARDS protocol), rather than defaulting to neuromuscular blockade, is the current evidence-supported approach. A meta-analysis specifically found NMBA improves oxygenation only after 48 hours and reduces barotrauma risk without affecting ICU weakness, but does not reduce ventilator-free days, mechanical ventilation duration, or mortality regardless of ARDS severity — reserve consideration for genuinely refractory dyssynchrony/hypoxemia despite these other measures being optimized first, recognizing this narrower use case has not itself been separately, rigorously tested.

12. Organ Support

Directly interacts with the ARDS protocol's lung-protective ventilation strategy, Pain Assessment & Sedation Strategy protocol (the deep sedation requirement this intervention imposes), and Early Mobilization & Rehabilitation protocol (the immobility cost) — this decision cannot be made in isolation from those three.

13. Disease-Specific Therapy

• Cisatracurium: 15 mg IV bolus followed by continuous infusion of 37.5 mg/hour for 48 hours — the specific regimen used in both major trials; if used, should be time-limited to this duration per the trial evidence rather than extended empirically
• Concomitant deep sedation is required throughout the infusion period — this should be explicitly planned and reassessed for prompt de-escalation once the 48-hour period concludes, per the broader light-sedation principles in Pain Assessment & Sedation Strategy protocol

14. Consultation Matrix

15. Monitoring Framework

• Clinical: ventilator synchrony, hemodynamic stability, and rhythm monitored closely during any neuromuscular blockade infusion given the specific cardiovascular adverse event signal from ROSE
• Escalation triggers: new arrhythmia, hemodynamic instability, or bradycardia during infusion → reassess continuation
• De-escalation criteria: 48-hour duration completed → discontinue and transition to light sedation per standard practice, not extended empirically

16. ICU Bundle Checklist

17. Complications

Early:

• Cardiovascular adverse events, specifically conduction system abnormalities (bradycardia, atrial fibrillation, heart block) and cardiac arrest — a real, quantified excess risk identified in ROSE (excess of 10 cardiovascular events, including 4 excess cardiac arrests)
• Requirement for deep sedation with its attendant hemodynamic and delirium risks (cross-reference Pain Assessment & Sedation Strategy and Delirium Screening & Management protocols)

Late:

• ICU-acquired weakness risk from combined paralysis and immobility (cross-reference Early Mobilization & Rehabilitation and Post-Intensive Care Syndrome protocols), though notably not found to be significantly different between groups in either major trial — a somewhat reassuring, if counterintuitive, finding given the strong a priori mechanistic concern about this specific complication

Prevention: reserving use for genuinely refractory cases after optimizing sedation/ventilation/proning first; explicit time-limited duration

Rescue: standard arrhythmia/hemodynamic instability management if a cardiovascular adverse event occurs during infusion

18. Escalation & De-escalation

Escalation: genuinely refractory dyssynchrony/hypoxemia despite optimized sedation, ventilation, and proning → consider time-limited (48-hour) neuromuscular blockade as a narrower, more individualized rescue measure rather than a routine early intervention.

De-escalation: 48-hour duration completed, or cardiovascular adverse event occurring → discontinue and transition to light sedation per standard practice.

19. ICU Discharge Criteria — Not Directly Applicable

Cross-reference ARDS and ICU Discharge Criteria & Step-Down protocols for the relevant discharge framework.

20. Documentation & Medicolegal Checklist

• Rationale for neuromuscular blockade use (or non-use) documented, particularly whether sedation/ventilation/proning optimization was attempted first
• Duration of infusion documented, confirming adherence to the 48-hour evidence-based limit
• Cardiovascular monitoring and any adverse events during infusion documented
• Transition plan to light sedation post-infusion documented

21. Key Guidelines

• Current guidance reflects a weak recommendation for early neuromuscular blockade in ARDS, predating full incorporation of ROSE's findings in some documents — clinicians should specifically weigh ROSE's more contemporary, larger evidence base alongside older guidance that may still substantially reflect ACURASYS-era practice assumptions

22. Landmark Trials

23. Controversies

• This is a genuinely instructive case of "the comparator changed, not just the intervention": unlike several other discordant-trial pairs in this library (e.g., ADRENAL vs. APROCCHSS, where population/regimen differences are the leading explanation), the ACURASYS-ROSE discordance is substantially explained by the standard-of-care comparator itself evolving between trials (deep sedation as usual care → light sedation as usual care) — this is a distinct, worth-naming pattern in evidence interpretation: an intervention's measured benefit can appear to diminish or disappear not because the intervention changed, but because the alternative it's being compared against improved independently.
• Whether a narrower, more refractory-population indication remains valid: current evidence supports avoiding routine early use, but has not specifically, rigorously tested neuromuscular blockade as a rescue measure in patients with genuinely refractory dyssynchrony/hypoxemia despite optimized sedation, ventilation, and proning — this narrower use case remains a plausible, individualized consideration rather than either a clearly supported or clearly refuted indication.
• The reassuring, somewhat counterintuitive ICU-acquired weakness finding: despite strong a priori mechanistic concern, neither trial found a significant difference in ICU-acquired weakness between groups — this specific concern, while mechanistically reasonable, has not been the primary driver of ROSE's neutral-to-harmful overall finding, which instead centers on the absence of mortality benefit and the cardiovascular signal.
• Physiological subphenotyping remains investigational: post-hoc analyses examining ventilatory ratio and specific PaO2/FiO2 thresholds as potential effect modifiers represent an active area of investigation into whether specific ARDS subphenotypes might still benefit from neuromuscular blockade, but this has not yet translated into a validated, clinically actionable selection tool.

24. References

1. Papazian L, Forel JM, Gacouin A, et al; ACURASYS Study Investigators. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363(12):1107-1116.
2. National Heart, Lung, and Blood Institute PETAL Clinical Trials Network; Moss M, Huang DT, Brower RG, et al. Early neuromuscular blockade in the acute respiratory distress syndrome (ROSE). N Engl J Med. 2019;380(21):1997-2008.
3. Guervilly C, Bisbal M, Forel JM, et al. Effects of neuromuscular blockers on transpulmonary pressures in moderate to severe acute respiratory distress syndrome. Intensive Care Med. 2017.
4. Neuromuscular blockade in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials. 2020.
5. Park M, et al. Early neuromuscular blockade in moderate to severe acute respiratory distress syndrome: do not throw the baby out with the bathwater! J Thorac Dis. 2019.
6. The prognostic value of early measures of the ventilatory ratio in the ARDS ROSE trial. 2022.
7. The Washington Manual of Critical Care, 4th ed. 2025 — ARDS chapter.
8. ICU Protocols: A Step-wise Approach, 2nd ed. — acute respiratory distress syndrome chapter.